ArticleScientific reports2026
Structural basis for diosgenin as an inverse agonist of retinoic acid receptor-related orphan receptor γ.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Retinoic acid receptor-related orphan receptor γ (RORγ) is a member of the nuclear receptor superfamily involved in many physiological activities such as metabolic and autoimmune diseases, and therefore a potential therapeutic drug target. Here we report that the steroidal sapogenin, diosgenin, a novel ligand for RORγ, inhibits the transcriptional activity of the RORγ with distinctive properties in coregulator recruitment. Biochemical and cell-based studies indicated that diosgenin functions as a selective RORγ inverse agonist by inducing both coactivator and corepressor binding to RORγ, thereby uncovering a molecular mechanism for the actions of this natural compound. Further, the crystal structure of diosgenin complexed with the ligand-binding domain of RORγ reveals a unique binding mode including the active conformation of AF-2 helix and the conformational shift of Helix 11. Structural and functional studies suggest the plasticity of RORγ pockets in recognizing ligands and the vital roles of the backbone of diosgenin in recognizing RORγ. Our results provide a unique inverse agonist template of RORγ with high selectivity and efficacy, which contributes to further drug design and optimization targeting RORγ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.